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http://www.biomedcentral.com/1471-2369/14/178RESEARCH ARTICLE Open AccessHyperphosphatemia is associated with anemia in
adults without chronic kidney disease: results from
the National Health and Nutrition Examination
Survey (NHANES): 2005–2010
Janet M WojcickiAbstract
Background: Hyperphosphatemia, serum phosphorus ≥ 4.4 mg/dL, is associated with increased risk for chronic
kidney disease and cardiovascular disease. Previous studies have shown a weak association between dietary
phosphorus intake and serum phosphorus concentrations. While much less common in the general population,
hypophosphatemia (< 2.5 mg/dL) may be associated with metabolic syndrome and obesity.
Methods: Using three cycles from the National Health and Nutrition Examination Survey (NHANES) (2005–2010),
this study evaluated independent risk factors for hyperphosphatemia and hypophosphatemia.
Results: Risk factors for hyperphosphatemia included higher adjusted calcium (OR 2.90, 95% CI 2.43-3.45),
increasing cholesterol (OR 1.003, 95% CI 1.001-1.005), female gender (OR 1.61, 95% CI 1.39-1.87) and low
hemoglobin (OR 1.52, 95% CI 1.17-1.98). Advanced age was protective (OR 0.98, 95% CI 0.977-0.987). Models that
included fasting serum glucose found lower body mass index (BMI) to be protective (OR 0.97, 95% CI 0.96-0.99)
and adjusting for serum vitamin D and parathyroid hormone removed the association with low hemoglobin and
BMI. Risk factors for hypophosphatemia included the following protective factors: higher albumin (OR 0.56, 95% CI
0.35-0.93), higher BUN (OR 0.90, 95% CI 0.86, 0.95), corrected calcium (OR 0.38, 95% CI 0.23-0.63) and female gender
(OR 0.47, 95% 0.24-0.94). In men, higher fasting glucose levels increased risk (OR 1.01, 95% CI 1.0004-1.01).
Conclusion: This study is the first to show an association between low hemoglobin levels and increased risk for
hyperphosphatemia among individuals without chronic kidney disease. We did not find any association between
diabetes mellitus, increasing BMI or fasting glucose levels and hypophosphatemia.
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Determinants of serum phosphorus concentrations include
dietary intake, gastrointestinal absorption of phosphorus,
urinary excretion and shifts in phosphorus between the
intracellular and extracellular spaces [1]. Previous studies
have found only a weak association between serum phos-
phate concentrations and dietary phosphorus intake [2].
There has been much focus on trying to better understand
the risk factors for hyperphosphatemia, as elevated phos-
phate levels are associated with progress of chronic kidneyCorrespondence: wojcickij@peds.ucsf.edu
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reproduction in any medium, provided the ordisease (CKD) and end stage renal disease (ESRD) [3]. Even
levels in high normal range (≥ 4 mg/dL & < 4.5 mg/dL) have
been found to be associated with increased risk for chronic
kidney disease [3]. Elevated serum phosphorus is also asso-
ciated with cardiovascular disease risk through the potential
mechanism of vascular calcification via upregulation of
core binding factor a-1 in vascular smooth muscle cells
in both those with and without CKD [4].Risk factors for hyperphosphatemia: poverty and
environment
A recent study evaluating risk factors for hyperphospha-
temia found an association between elevated phosphateThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mediary factors associated with poverty would simul-
taneously increase phosphate levels [2]. It is possible
that increased environmental exposures to pesticides
and phenols may mediate the relationship between the
association found between low socioeconomic status
and hyperphosphatemia. Previous studies found that
urinary excretion of environmental phenols (specifically
bisphenol A (BPA) and triclosan) were lower in individ-
uals with reduced estimated glomerular filtration rate
(eGFR) although it is not clear if they could similarly be
associated with increased serum phosphorus levels [5].
Moreover, these relationships have not been investi-
gated in adults with normal eGFR.Anemia and hyperphosphatemia in ESRD
In patients with ESRD and kidney transplant recipients, a
previous study [6] found a relationship between hyper-
phosphatemia and anemia. Various components of CKD
mineral and bone disorders (CKD-MBD) may result in a
direct suppressive effect on erythropoiesis, resulting in
anemia, including low vitamin D, calcium and increased
serum parathyroid hormone levels. It is not clear whether
the relationship between hyperphosphatemia and anemia
is mediated by other aspects of CKD-MBD in CKD
patients. A study of the relationship between kidney
transplant recipients and high-normal phosphate levels
found a significant association of higher serum phos-
phorus level with lower hemoglobin, independent of
other factors associated with CKD-MBD and known
determinants of anemia [6]. Kovesdy et al., [6] theorize
that the relationship between phosphorus and anemia
may be mediated by uremic polyamine metabolism. Poly-
amines are uremic toxins that inhibit erythropoiesis [7].
Higher levels of polyamines as a result of phosphorus
levels could explain the relationship between higher
phosphorus levels and anemia. Meanwhile, although
these studies suggest an important relationship between
hyperphosphatemia and anemia in specific types of pa-
tients, there are no studies evaluating the relationship
between hyperphosphatemia and anemia in patients
without kidney disease.Female gender and hyperphosphatemia
Other known risk factors for hyperphosphatemia include
female gender although the reasons for this association
are unclear [8]. One study suggests that estrogen may
act directly to suppress sodium-dependent phosphate
absorption in the renal proximal tubules inducing phos-
phaturia and decreased serum phosphate; women who
are post-menopausal and estrogen deficient would be at
increased risk for hyperphosphatemia [9].Risk factors for hypophosphatemia
In contrast with hyperphosphatemia, hypophosphatemia
is much less common in the general, non-hospitalized
population. Low serum phosphate levels are associated
with reduced cardiac output and also with risk for
arrhythmia [10]. However, recent studies have suggested
that hypophosphatemia is more common than previously
recognized as there may be an association between obesity
and the metabolic syndrome and risk for hypophospha-
temia [11]. Haglin theorizes that a low serum phosphate
level limits phosphorylation of carbohydrate intermediates
in glycolysis and glycogenesis and chronic hypophospha-
temia inhibits glucose transport potentially resulting in
diabetes mellitus and hypertension [11].
The aim of the present study was to evaluate potential
risk factors for hyperphosphatemia and hypophospha-
temia in a large population based survey of patients
without kidney disease, the National Health and Nutrition
Examination Surveys (NHANES) from 2005–10, including
anemia as well as investigate the possible relationship
between exposure to environmental phenols, specific-




The NHANES is a nationally representative, cross-sec-
tional survey, which was designed by the National Center
of Health Statistics (NCHS) to be a representative sample
of the non-institutionalized US population and used to
assess the health and nutritional status of Americans. A
total of 31,034 adults and children participated in
NHANES 2005–2010 (three cycles 2005–6; 2007–2008;
2009–10). These NHANES cycles were approved by the
Institutional Review Board of the National Center for
Health Statistics. All NHANES participants who were ≥18
years of age provided informed consent.
Participants <18 years of age were excluded from this
study (n =10,148). Participants who stated that they had
been told that they had weak/failing kidneys or had
received dialysis in the past 12 months (n = 534) were
also excluded from the study as were those with an
estimated glomerular filtration rate <60 (n=486) and a
serum creatinine > 1.3 mg/dL (n = 486). Vitamin D and
parathyroid measurements were only available from the
2005–6 cycle (n = 5061) and ferritin and transferrin
receptor saturation were only available on women for
2005–2010 for a smaller sample size (n = 8,411). For
the environmental phenols and pesticides, only one
third of the sample was used per cycle (approximately
2,500 participants depending on the years surveyed
without the above exclusions) and special sampling
weights provided by NHANES were used for each
cycle. For the fasting glucose measurements, only those
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were included in sample (approximately 3,000 per cycle
without the above exclusions) (Figure 1). As described
below in results, the exact number of participants
varied for different analyses that were conducted.
Study variables
For the laboratory measurement, different methods were
used in the first cycle (2005–6) versus subsequent cycles
(2007–8; 2009–10).
Biochemistry
In NHANES 2005–6, serum creatinine, blood urea nitrogen
(BUN), calcium, total cholesterol, phosphorus, uric acid
and albumin were measured using the Beckman Synchron
LX20 method (Brea, CA) [12]. Similarly, total calcium and
uric acid were measured with a Beckman Synchron ana-
lyzer (Brea, CA). Different laboratory methods were used
for calculating creatinine as described below depending
on year of NHANES survey; however, all of these were
standardized so that they could be combined for analyses.
Creatinine was calculated in 2005–6, 2007–8, 2009–10
using the Jaffe rate method (kinetic alkaline picrate) to
determine the concentration of creatinine in serum
where the creatinine calibration was traceable to an
isotope dilution mass spectrometry (IDMS) reference
method [12-14]. In 2008 and 2009–10, the Beckman
DxC800 was used. In 2005–6 and 2007, the Beckman
LX-20 was used, however, a Deming regression was
applied to standardize creatinine values between 2005–
6 and 2007 and 2008, and 2009–10. In these years
when the LX-20 was used, standard creatinine values
(mg/dL) were corrected using the following equation: -
0.016+0978 * (NHANES 05–06 uncalibrated serum cre-
atinine, mg/dL) [12,13]. In 2007–2010, albumin, calcium,
total cholesterol, phosphorus, uric acid and blood ureaNHANES 2005-2010 (n=31,034)
The following participants were excluded from the
study:
1. Participants < 18 years of age (n=10,148)
2.  Those who had weak/failing kidneys or had
received dialysis (n=534)
3.  Those with a GFR <60 (n=486) and
serum creatinine >1.3mg/dL (n=486)
Figure 1 Inclusion and exclusion of NHANES 2005-2010 participants.nitrogen (BUN) were measured using the DxC800 method
[13,14]. Corrected calcium values were calculated for
participants with albumin levels <3.4 g/dL. In 2009–10,
Glycohemoglobin measurements were performed on
the A1c 2.2 Plus Glycohemoglobin Analyzer (Toshoh
Medics, Inc., 347 Oyster Pt. Blvd., Suite 201, So. San
Francisco) [15]. For the early cycles (2005–8), glyco-
hemoglobin measurements were performed on the A1c
G7 HPLC Glycohemoglobin Analyzer (Tosho Medics,
Inc., 347 Oyster Pt. Blvd., Suite 201, So. San Francisco)
[16,17]. C-reactive protein was quantified by latex-
enhanced nephelometry in all years. Particle-enhanced
assays were based on the reaction between a soluble an-
alyte and the corresponding antigen or antibody bound
to polystyrene particles. For the quantification of CRP,
particles consisting of a polystyrene core and a hydro-
philic shell were used to link anti-CRP antibodies cova-
lently [18-20]. Ferritin measurements were conducted
using the Roche/Hitachi 912 clinical analyzer in all years
[21-23] and soluble transferrin receptor was measured
with immune-turbidimetry using Roche kits on the
Hitachi 912 clinical analyzer [24-26]. Fasting glucose
concentration was determined by a hexokinase method
in all years [27-29] and the fasting blood test was
performed after a 9 hour fast. In 2005–6, parathyroid
hormone levels were evaluated using the Elecysys 1010
analyzer using the ECL/Origen electrochemiluminescent
process [30] and 25-hydroxyvitamin D (25-OH-Vitamin
D) was assessed by the Diasorin assay using a two-step
procedure [31].Environmental data
The environmental phenols (bisphenol A (BPA), benzo-
pheonone-3 (BP-3) and one cholorphenols triclosan were
measured in all years using solid phase extraction coupledIncluded: n=19,380
1.  Vitamin D and parathyroid alone 
(n=5,061)       
2.  Ferritin and transferrin saturation
(n=8,411)
3.  Environmental phenols and pesticides
(n=5,353)
4.   Fasting glucose measurements (n=7,667)
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[32-34].24-hour dietary recalls
Two 24 -hour dietary recalls were used to assess the in-
take of specific micronutrients including phosphorus.
In order to ensure accuracy, the dietary recall interview
included a set of 3 dimensional measuring guides and
the interview asked if the dietary intake was usual or
unusual for that person and then the material is pro-
vided as an attachment as described in the NHANES
documentation [35]. Other measures are also in place,
including periodically audiotaping the interviews to ensure
that methods are being appropriately followed [35]. The
mean intake of phosphorus was subsequently calculated
averaging over two days.Calculations and definitions
For all years, the estimated glomerular filtration rate was
then calculated using the Modification of Diet in Renal
Disease Study equation [36], which is eGFR (mL/min/m
[2]) =175.0×(Scr)-1.154 × age-0.203 × 0.742 (if female) × 1.212
(if black). Furthermore, the CKD-Epi formula was also
used to estimate GFR where eGFR=144 × min (SCr/k,1)a ×
max (SCr/k,1)-1.209 × 0.993Age [1.018 if Female] × [1.159 if
Black] [37]. Low hemoglobin was defined as <12 g/dL for
women and <13 g/dL for men. Low hematocrit was de-
fined as < 36% for women and < 41% for men. Low ferritin
was defined as < 12 ng/mL for women and men and high
transferrin receptor saturation defined as > 4.6 g/L.
Demographic information was also collected by NHA
NES including information on the participants’ gender, age,
race/ethnicity with race/ethnicity defined as non-Hispanic
white, non-Hispanic black, Mexican-American, other
Hispanic and other race. Body mass index was calculated
based on weight and height measurements with weight
(kilograms) divided by height (meters squared). Diabetes
mellitus was defined as a self-reported physician diagnosis
of diabetes at the time of the interview. Poverty to income
ratio was used as the main variable to assess poverty sta-
tus, which is an index calculated by dividing family income
by a poverty threshold specific to family size. Living in
poverty was defined as having a poverty-to income ratio <
1. Obesity was defined as having a body mass index
(BMI) ≥ 30 kg/m [2]. Diabetes mellitus, kidney disease
(“failing kidneys”) and dialysis use was defined through
self-report, with information collected via questionnaire
format.
Steroid use was categorized as yes if any participant
reported the use of prednisone, prednisolone, methyl-
prednisolone, or methylprednisolone acetate within the
last 30 days. This data was extracted from the medica-
tion questionnaire.Statistical analysis
Serum phosphate levels were dichotomized by presence
(≥ 4.4 mg/dL) or absence (< 4.4 mg/dL & ≥ 2.5 mg/dL)
of hyperphosphatemia or presence (< 2.5 mg/dL) or ab-
sence (≥ 2.5 mg/dL & <4.4 mg/dL) of hypophosphatemia.
Additionally hyperphosphatemia was also evaluated in
relationship to lower levels of serum phosphate (< 3.5 mg/
dL). Bivariate analyses were conducted for risk factors
for hyperphosphatemia or hypophosphatemia and in-
cluded an evaluation of biochemical, sociodemographic,
pesticide and phenol exposure and health history and
dietary variables. Variables that were significant at
p < 0.05 were included in multivariate logistic regression
models analyzing independent risk factors for hyper-
phosphatemia or hypophosphatemia. All analyses were
conducted using Stata 12.0.
Sample weights were used as provided by NHANES
in the analysis to combine weights from all three cycles
following the NHANES analytic guidelines [38]. As de-
scribed above, special weight were used for the phenol
and pesticide samples and also for any analysis that
included fasting glucose levels. As vitamin D and para-
thyroid hormone levels were only available for the
2005–6 cycle, all analysis that included either of these
variables used the sampling weights from the 2005–6
cycle alone. The study was exempted from approval by the
Committee on Human Research (CHR) at the University
of California, San Francisco (UCSF).
Results
There were 19,380 persons ≥18 years of age from the
three cycles of the NHANES (2005–2010) that were
included in the analysis after exclusions based on age,
laboratory parameters or self-reported conditions, although
a smaller number was available in multivariate analyses
based on missing data for certain parameters. A smaller
number from the 2005–6 cycle included data on vitamin
D and parathyroid hormone (n = 5,061), as well as
those that had morning blood draw for fasting glucose
(n= 7,667) and were assessed for environmental phenol
exposures (n = 5,353). One hundred and forty-four re-
ported current use of oral steroids > 30 days, which repre-
sented a weighted percent of 0.50% (95% CI 0.41-0.61).
In the total population evaluated, 15.29% (95% CI 14.23-
16.41) had hyperphosphatemia (phosphorus ≥ 4.4 mg/dL)
and 0.59% (95% CI 0.43-0.82) had hypophosphatemia
(phosphorus ≤ 2.5 mg/dL).
Risk factors for hyperphosphatemia
In bivariate analysis, risk factors for hyperphosphatemia
included higher levels of albumin (p < 0.01), higher vita-
min D (p = 0.01), lower parathyroid hormone (p = 0.02),
higher corrected calcium (< 0.01), lower fasting glucose
(< 0.01) and lower hemoglobin levels (p = 0.03) (Table 1).
Table 1 Association between hyperphosphatemia and selected biochemical, socio-demographic and health
history variables
Phosphorus ≥ 4.4 mg/dL Phosphorus < 4.4 mg/dL P value
Means±SE or % Means±SE or %
Biochemical
Albumin (g/dL) 4.31±0.01 4.26±0.01 <0.01
Blood urea nitrogen (BUN) (mg/dL) 12.80±0.16 12.66±0.40 0.74
BUN ≥ 20 mg/dL 6.78 8.63 0.51
Vitamin D (25-0H-D) (ng/ml) 24.45±0.51 22.81±0.60 0.01
Vitamin D <10 (25-OH-D) (ng/ml) 4.05 5.58 0.12
Vitamin D >30 (25-OH-D) (ng/ml) 21.82 16.68 0.10
Parathyroid hormone(pg/mL) 38.25±1.48 44.09±1.64 0.02
Total calcium (mg/dL) 9.57±0.01 9.44±0.01 <0.01
Corrected calcium (mg/dL) 9.59±0.01 9.44±0.01 <0.01
Calcium >10 mg/dL 7.19 3.99 <0.01
Cholesterol (mg/dL) 202.14±1.15 194.90±1.88 <0.01
Serum creatinine (mg/dL) 0.84±0.004 0.86±0.01 0.11
Uric acid (mg/dL) 5.29±0.04 5.45±0.08 0.10
eGFR (MDRD) 94.57±1.01 92.31±0.73 0.051
eGFR (CKD-Epi) 98.16±0.60 95.90±1.09 0.052
Hemoglobin A1c 5.49±0.02 5.54±0.03 0.15
Fasting glucose (mg/dL) 99.52±0.86 103.99±0.52 <0.01
C-reactive protein (mg/dL) 0.36±0.02 0.37±0.01 0.55
Anemia and Iron
Low hemoglobin levels* 6.62 5.04 0.03
Low hematocrit levels^ 13.2 11.44 0.07
Low hemoglobin or hematocrit 13.51 11.69 0.08
Low Ferritin <12 ng/mL 12.78 11.96 0.60
High Transferrin Sat > 4.6 g/L 16.02 14.36 0.36
Socio-demographics
Gender
Male 12.73 87.27 <0.01
Female 17.66 82.34
Age (years) 42.34±0.49 45.91±0.65 <0.01
Ethnicity
Mexican 14.16 85.84 0.56
Other Hispanic 14.24 85.76
White 15.29 84.71
Black 15.16 84.84
Other Race 16.65 83.35
Poverty income Ratio 3.07±0.06 3.08±0.05 0.90
Poverty income Ratio <1 14.54 13.07 0.14
Health History and Diet
Body Mass Index (kg/m2) 27.86±0.20 28.75±0.25 <0.01
Obesity (BMI ≥ 30 kg/m2) 31.32 36.08 0.08
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Table 1 Association between hyperphosphatemia and selected biochemical, socio-demographic and health
history variables (Continued)
Self reported diabetes
Yes 7.76 92.24 0.07
No 16.32 83.68
Phosphorus Intake mg/day 1410.25±21.91 1364.69±23.43 0.14
Steroids (>past 30 days, any) 0.70 0.44 0.20
Envrionmental Phenols
Urinary Benzopheone-3 (ng/mL)
≤6 15.62 84.38 0.13
>6 & ≤30.1 13.07 86.93
>30.1 16.98 83.02
Urinary Bisphenol A (ng/mL)
<1.3 16.05 83.95 0.72
≥1.3 & <3 14.45 85.55
≥3 15.47 84.53
Urinary Tricolsan (ng/mL)
≤4.2 15.78 84.22 0.63
>4.2 & <23.3 16.07 83.93
≥23.3 14.51 85.49
*Low hemoglogin is defined as <12g/dL for women and <13g/dL for men.
^ Low hematocrit was defined as <36% for women and <41% for men.
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risk for hyperphosphatemia with 6.62% of those having
a phosphate ≥ 4.4 having low hemoglobin in contrast
with 5.04% of those having phosphate less than 4.4
but > 2.5 (p = 0.03) (Table 1). Women were more likely to
have high serum phosphate (17.66% versus 12.73%,
p < 0.01) as were younger participants (42.34±0.49 ver-
sus 45.91±0.65 years, p < 0.01). Lower body mass index
(BMI) was associated with increased risk for hyperphos-
phatemia (27.86±0.20 kg/m [2] versus 28.75±0.25 kg/m
[2]; p < 0.01).
In examining the association between urinary pesticide
and phenol exposures, there was no association between
levels of bisphenol A (BPA), benzopheone-3 (BP-3) and
tricolsan and hyperphosphatemia. We also evaluated risk
factors for high serum phosphate ≥ 4.4 in comparison to
those with low serum phosphate < 3.5 finding similar
risk factors to those described above with the exception
of a higher BUN and a lower uric acid and serum cre-
atinine in those with hyperphosphatemia in comparison
with those with a serum phosphate < 3.5. In multivariate
logistic regression analysis (n=15,578), increasing cal-
cium (OR 2.90, 95% CI 2.43-3.45), higher cholesterol
(OR 1.003, 95% CI 1.001-1.005), female gender (OR
1.61,95% CI 1.39-1.87) and low hemoglobin (OR 1.52,
95% CI 1.17-1.98) were associated with increased risk
for hyperphosphatemia (Table 2). Older age was pro-
tective against hyperphoshatemia (OR 0.98, 95% CI 0.977-0.987) as was lower GFR (OR 0.996, 95% CI 0.992-0.999)
(Table 2). Adjusting for serum glucose levels using a
smaller sample size (n=7,631), independent risk factors for
hyperphosphatemia included corrected calcium (OR 3.59,
95% CI 2.55-5.05), female gender (OR 1.83, 95% CI 1.51-
2.23) and low hemoglobin (OR 1.52, 95% CI 1.003-2.29).
When the model used a smaller sample size (n=5,019) but
included vitamin D and parathyroid hormone levels, lower
BMI was no longer protective and low hemoglobin no
longer increased risk (Table 2). Similar risk factors were
present for hyperphosphatemia when compared with
serum phosphate levels < 3.5 in multivariate analysis
although increasing serum BUN was also associated
with hyperphosphatemia. In both the larger model and
the model with fasting glucose, low hemoglobin was as-
sociated with increased risk (OR 1.43, 95% CI 1.09-1.86
for large model and OR 1.60, (95% CI 1.07-2.40) for the
model with fasting glucose (Table 3)). In a multivariate
model with serum vitamin D and parathyroid hormone,
increasing parathyroid hormone was associated with
decreased risk (OR 0.99, 95% CI 0.98-0.9996) (Table 3).
Hypophosphatemia
Risk factors for hypophosphatemia included a lower
albumin (p < 0.01), lower BUN (p=0.02), higher corrected
calcium level (p < 0.01) and higher uric acid (p = 0.02).
Lower ferritin was protective (p < 0.01), as was being
female (p = 0.01) and having a lower BMI (p < 0.01). Being
Table 2 Multivariate logistic regression analysis for risk factors for phosphorus ≥ 4.4
Variables OR 95% CI
Model 1 (n =15,578) Model 2 (n =7,631) Model 3 (n = 5,019)
Albumin (g/dL) 1.14 (0.92-1.41) 0.68 (0.50-0.94)b 1.22 (0.96-1.55)
Corr. Calcium (mg/dL) 2.90 (2.43-3.45)a 3.59 (2.55-5.05)a 2.95 (2.14-4.05)a
Cholesterol (mg/dL) 1.003 (1.001-1.005)a 1.0003 (0.998-1.003) 1.004 (1.00-1.01)b
Gender (Female) 1.61(1.39-1.87)a 1.83 (1.51-2.23)a 1.66 (1.25-2.17)b
Age, years 0.98(0.977-0.987)a 0.98 (0.97-0.99)a 0.98 (0.971-0.99)a
BMI (kg/m2) 0.99 (0.98-1.005) 0.97 (0.95-0.99)b 0.99 (0.96-1.02)
Low Hemoglobin 1.52 (1.17-1.98)a 1.52 (1.003-2.29)b 1.48 (0.87-2.51)
GFR (CKD-Epi) 0.996 (0.992-0.999)b 0.996 (0.989-1.003) 0.99 (0.989-1.00)
Fasting Glucose (mg/dL) 0.999 (0.995-1.002)
Vitamin D 25-OH-D (ng/ml) 1.00 (0.99-1.01)
Serum PTH (pg/ml) 0.99 (0.98-1.00)
ap<0.01.
bp<0.05.
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analysis for independent risk factors for hypophosphatemia
included the following factors: albumin and BUN were
protective (OR 0.56, 95% CI 0.35-0.93 and OR 0.90,
95% CI 0.86-0.95, respectively) as was higher corrected
calcium (OR 0.38, 95% CI 0.23-0.63) and being female
(OR 0.47, 95% CI 0.24-0.94) (Table 5). With low ferritin
(<12 g/L) in the model, increased creatinine was signifi-
cant (OR 23.48, 95% CI 1.10-501.47) and low ferritin
was protective (OR 0.14, 95% CI 0.04-0.45). Including
parathyroid hormone into the model, gender was no
longer significant but higher BUN continued to be
protective (OR 0.83, 95% CI 0.76-0.91) as did corrected
calcium (OR 0.22, 95% CI 0.07-0.73) and higher uricTable 3 Multivariate risk factors for phosphorus ≥ 4.4 mg/dL
Variable
Model 1 (n=12236)
Albumin (g/dL) 1.16 (0.92-1.45)
BUN (mg/dL) 1.08 (1.06-1.09)a
Corr. Calcium (mg/dL) 3.42 (2.82-4.15)a
Cholesterol (mg/dL) 1.003 (1.002-1.005)a
Uric Acid (mg/dL) 0.99 (0.94-1.05)
Gender (Female) 1.92 (1.65-2.24)a
Age (Years) 0.98 (0.976-0.98)a
BMI (kg/m2) 0.99 (0.98-1.004)
Low Hemoglobin 1.43(1.09-1.86)a
Creatinine (ng/mL) 0.98 (0.65-1.48)
Fasting Glucose (mg/dL)
Vitamin D- 25-OH-D (ng/mL)
Parathyroid Hormone (pg/mL)
ap<0.01.
bp<0.05.acid was associated with increased risk (OR 1.35, 95%
1.09-1.66). Stratifying based on gender, males were at
increased risk for hypophosphatemia with increasing
glucose levels (OR 1.01, 95% CI 1.0004-1011); this
association was not present in females.
Discussion and conclusion
In these cycles of NHANES, there was relatively high
percentage of individuals without chronic kidney disease
who had hyperphosphatemia (15.29%) in comparison
with previous analyses of earlier cycles (NHANES III –
1988–1994) which found 14% in the US population
without excluding those with CKD and using a lower
threshold ≥ 4.0 mg/dL [39]. The higher percentage mayin comparison with phosphorus <3.5 mg/dL) (n=12335)
Odds Ratio (OR) 95% CI
Model 2 (n=6351) Model 3 (n=3752))
0.65 (0.46-0.90)b 1.24 (0.98-1.59)
1.07 (1.04-1.10)a 1.08 (1.05-1.12)a
4.32 (3.15-6.00)a 3.61 (2.45-5.93)a
1.0005 (1.00-1.003)b 1.00 (1.00-1.01)b
1.11 (1.01-1.22)b 1.00 (0.89-1.13)
2.48 (1.94-3.16)a 1.95 (1.45-2.62)a
0.97 (0.967-0.98)a 0.98 (0.97-0.99)a
0.96 (0.94-0.98)a 0.99 (0.96-1.02)
1.60 (1.07-2.40)b 1.28 (0.68-2.40)




Table 4 Association between hypophosphatemia and selected biochemical, socio-demographic and health
history variables
Phosphorus >2.5 mg/dL Phosphorus ≤ 2.5 mg/dL P Value
Variable Means±SE or % Means±SE or %
Biochemical
Albumin (g/dL) 4.18±0.02 4.26±0.007 <0.01
BUN (mg/dL) 12.69±0.41 11.48±0.30 0.02
BUN≥20 (mg/dL) 2.26 8.46 0.02
Vitamin D (25-0H-D) (ng/mL) 21.10±1.34 22.82±0.60 0.13
Vitamin D (25-OH-D) <10 ng/mL 11.16 5.60 0.14
Vitamin D (25-OH-D) >30 ng/mL 12.21 16.73 0.44
Corrected calcium (mg/dL) 9.44±0.01 9.33±0.03 <0.01
Calcium>10 (mg/dL) 4.32 3.99 0.82
Parathyroid pg/mL 44.02±1.65 54.09+±4.74 0.07
Cholesterol (mg/dL) 194.95±1.91 191.37±3.24 0.35
Creatinine (mg/dL) 0.86±0.01 0.89±0.01 0.10
Uric Acid (mg/dL) 5.45±0.0.08 5.71±0.10 0.02
Hemoglobin A1c 5.62±0.10 5.54±0.03 0.42
Fasting glucose (g/mL) 109.26±3.83 103.88±0.52 0.17
eGFR(MDRD) 92.35±0.73 91.58±1.57 0.69
eGFR (CKD-Epi) 96.25±0.96 95.88±1.83 0.86
C-Reactive Protein (mg/dL) 0.37±0.01 0.61±.16 0.15
Anemia and Iron
Low Hemoglobin* 4.18 5.06 0.59
Low Hematocrit^ 1.03 1.14 0.63
Low Hemoglobin 1.05 1.17 0.67
Or Hematocrit
High Trans Sat>4.6 ng/dL 12.27 14.35 0.71
Low Ferritin <12 g/L 1.85 12.2 <0.01
Sociodemographic
Gender
Male 97.44 2.56 0.01
Female 98.60 1.40
Age (Years) 44.23±1.01 45.93±065 0.16
Ethnicity
Mexican 2.07 97.93 0.58
Other Hisp 1.94 98.06
White 1.91 98.09
Black 2.07 97.93
Other Race 2.82 97.18
PIR 2.87±0.13 3.08±0.05 0.14
PIR<1 (poverty) 12.60 13.05 0.83
Health History
BMI (kg/m2) 30.01±0.49 28.74±0.25 <0.01
Obese 42.19 36.05 0.06
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Table 4 Association between hypophosphatemia and selected biochemical, socio-demographic and health
history variables (Continued)
Diabetes
Yes 1.41 98.59 0.53
No 2.01 97.99
Phosphorus Intake (mg) 1412.27±57.59 1363.72±23.20 0.35
Steroid Use




≤6 98.44 1.56 0.18
>6 & ≤30.1 97.19 2.81
>30.1 96.70 3.30
Urinary Bisphenol A (ng/mL)
<1.3 97.91 2.09 0.61
≥1.3 & <3 97.02 2.98
≥3 97.04 2.96
Urinary Tricolsan (ng/mL)
≤4.2 96.32 3.68 0.18
>4.2 & <23.3 97.68 2.32
≥23.3 97.97 2.03
*Low hemoglobin is defined as <12 g/dL for women and <13 g/dL for men.
^ Low hematocrit was defined as <36% for women and <41% for men.
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an increased consumption of processed foods, with high
phosphate contents in the last 10–15 years [40,41].
Hyperphosphatmeia and anemia
This is the first study to evaluate risk factors for
hyperphosphatemia and hypophosphatemia in a large
population of US adults without chronic kidney disease.
While these results suggest some known factors associ-
ated with hyperphosphatemia including an associationTable 5 Multivariate logistic regression for phosphorus ≤2.5 m
Variable
Model 1 (n=13,502)
Albumin (mg/dL) 0.56 (0.35-0.93)b
BUN (mg/dL) 0.90 (0.86-0.95)b
Uric Acid (mg/dL) 1.04 (0.90-1.21)
Corr. Calcium (mg/dL) 0.38 (0.23-0.63)a
Gender (Female) 0.47 (0.24-0.94)a
BMI (kg/m2) 1.01 (0.99-1.03)
Creatinine (ng/mL) 3.19 (0.72-1419)
Low Ferritin (<12 g/L)
Parathyroid Hormone (pg/ml)
ap<0.01.
bp<0.05.with increasing calcium levels and female gender and a
reduced risk with age, we also found increased risk with
anemia, as indicated by low hemoglobin levels, as well
as an association with lower BMI. Previous population
based studies have found an association between kidney
function and anemia in adults with a eGFR < 60 mL/
minute but not in adults with normal kidney function
[42]. As such, we restricted our study to individuals
with a eGFR ≥ 60 mL/minute. The chronic inflammatory
state of kidney disease, including higher C-reactive proteing/dL
Odds Ratio (OR) 95% CI
Model 2 (n=4,385) Model 3 (n=4,223)
0.58 (0.21-1.58) 0.89 (0.23-3.44)
0.86 (0.76-0.98)b 0.83 (0.76-0.91)a
1.23 (0.92-1.66) 1.35 (1.09-1.66)a
0.77(0.25-2.36) 0.26 (0.07-0.88)b
1.00 0.56 (0.23-1.37)
1.01 (0.95-1.07) 1.00 (0.97-1.04)
23.48 (1.10-501.47)b 1.17 (0.03-39.53)
0.14 (0.04-0.45)b
1.01 (0.995-1.03)
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associated with lower hemoglobin levels [43,44]. While
our analysis did not include participants with kidney
disease, we did not find any association between signs
of inflammation including CRP levels, vitamin D and
hyperphosphatemia. Kendrick et al. [45] hypothesize that
as TNF-alpha interferes with normal erythropoisesis
and a decreased response to epoetin, higher vitamin D
levels could result in increased hemoglobin through a
down-regulation of TNF-alpha and other proinflammatory
cytokines.
Additionally, low vitamin D levels decrease gut phos-
phorus absorption, as vitamin D acts on intestinal epi-
thelial cells to increase intestinal absorption of calcium
and phosphorus, and hence may be associated with
hyperphosphatemia [46]. Additionally, low levels of vita-
min D and parathyroid hormone increase the transport of
phosphorus out of the renal cells through 3NA-HPO4
co-transporter type 2a (NPT-2a) and limit renal tubular
reabsorption additionally resulting in hyperphosphatemia
[47,48]. However, under conditions of normal phosphate
intake, as was observed with the NHANES population,
vitamin D does not stimulate jejunal phosphorus absorp-
tion; it is only in patients with chronic kidney disease or
low levels of vitamin D, that vitamin D administration can
increase phosphorus absorption. Because of the complex
relationship between these factors and phosphorus
absorption, we adjusted for vitamin D levels in addition to
parathyroid hormone in a smaller model examining risk
factors for hyperphosphatemia and hypophosphatemia.
In this adjusted model for hyperphosphatemia, the
association with low hemoglobin was no longer statisti-
cally significant, although it is possible that the smaller
model (only one third the size of the larger model) was
not sufficiently powered. When the association between
low hemoglobin and hyperphosphatemia was assessed
stratifying on vitamin D level > 30 ng/ml versus vitamin
D level ≤ 30 ng/ml, the odds ratios were not significantly
different in between models (OR 1.10 versus OR 1.29)
or in comparison with the adjusted model OR 1.33,
suggesting that neither confounding nor interaction plays
an important role in defining the inter-relationships
between serum phosphorus levels, hemoglobin and
vitamin D.
Ideally, future cycles of NHANES will include vitamin
D and parathyroid hormone levels tested in all partici-
pants, as this was one of the limitations of our study,
that we were unable to test these associations using one
cycle of NHANES.
It is not clear what mechanism is responsible for the
increased serum phosphorus levels associated with anemia.
Studies of hyperphosphatemia have been almost exclu-
sively in patients with kidney disease, however, given the
associations between hyperphosphatemia, cardiovasculardisease and increased mortality [49], it is important to
better understand the risk factors in the general popula-
tion, in addition to those with CKD. The mechanisms that
underlie the relationship between lower hemoglobin levels
and hyperphosphatemia need to be further studies in the
general population as they currently are unexplored.Hypophosphatemia
We found a low percentage of overall hypophosphatemia
in these cycles of NHANES (0.59%). There is limited data
on the prevalence of hypophosphatemia in the general
population, although approximately 2-20% of hospitalized
patients may have hypophosphatemia [50,51], with higher
percentages in ICU and critically ill patients.
In contrast to the studies by Haglin [11] and Haglin
et al., [52], we did not find any evidence to suggest associ-
ations between hypophosphatemia and the metabolic
syndrome although increasing BMI neared statistical
significance OR 1.01 (0.99-1.03). Haglin et al. found an
inverse correlation between serum phosphate and BMI
levels in women and an association between higher
serum glucose levels and hypophosphatemia in males
[11]. Similarly, however, we did find important gender-
specific differences in relation to serum phosphorus
levels. We found an increased risk in men alone for
fasting glucose levels and hypophosphatemia (results
not shown). Increased BMI neared statistical significance
for association with hypophosphatemia in women control-
ling for fasting glucose levels (OR 1.06, 95% CI (0.998-1.13)
(results not shown). Haglin et al. [52] hypothesize that the
mechanism that cause hypophosphatemia in relation to
obesity is an overconsumption of a diet with low nutrient
density or phosphate depletion due to low protein intake
and in animal experiments, hypophosphatemia is associ-
ated with glucose uptake [47] and hypophosphatemia is
related to reduced glucose tolerance [53]. Lastly, we did
not find any association between phosphate levels and
steroid use, in contrast with the study by Skversky et al.,
which found an inverse association between steroid use
and vitamin D levels [54].
Future studies need to be longitudinal in nature so as to
better understand the mechanisms involved in explaining
the relationship between hypophosphatemia and either
obesity or serum glucose levels based on gender. Our
current understanding is associative in nature and does
not evaluate the temporality of relationships.Competing interests
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